Methylphenidate and Risk of Serious Cardiovascular Events in Adults

From the Center for Clinical Epidemiology and Biostatistics, the Department of Biostatistics and Epidemiology, and the Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; HealthCore, Inc., Wilmington, Del.; and PolicyLab: Center to Bridge Research, Practice, and Policy, Children's Hospital of Philadelphia.All authors received salary support from Shire through their employer. Dr. Schelleman has had travel to scientific conferences paid for by University of Pennsylvania's pharmacoepidemiology training program through funds contributed by Abbott, Amgen, Hoffman LaRoche, Novartis, Pfizer, Sanofi Pasteur, and Wyeth. Dr. Bilker has consulted for Johnson & Johnson. Dr. Kimmel has received grant funding or consulting fees from the Aetna Foundation, AstraZeneca, Bristol-Myers Squibb, Centocor, Johnson & Johnson, Novartis, Merck, and Pfizer. Drs. Daniel and Cziraky are employed by HealthCore, Inc., which conducts research for and receives funding from pharmaceutical manufacturers for research services. Dr. Strom has received research support from or consulted for Abbott, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, GlaxoSmithKline, Novartis, NPS Pharma, Nuvo Research, Orexigen, Pfizer, Shire, Takeda, Teva, and Vivus and has received contributions to University of Pennsylvania's pharmacoepidemiology training program from Abbott, Amgen, Hoffman LaRoche, Novartis, Pfizer, Sanofi Pasteur, and Wyeth. Dr. Hennessy has received grant funding from Abbott and has consulted for Abbott and Teva.Funded through a sponsored research agreement with Shire Development, Inc., with infrastructure support provided by NIH (Clinical and Translational Science Award 5KL2RR024132).